drugset / Trial / NCT01391143
Safety Study of MGA271 in Refractory Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors.
Timeline
- Start
- 2011-07
- Primary completion
- 2019-04-18
- Completion
- 2019-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoblituzumab | Monoclonal antibody | — | Intravenous |